Pirolli R, Teixeira V, de Alencar L, et al. - Given carboplatin and dose-dense weekly paclitaxel (ddCT) conferred different advantages, as first line treatment of ovarian cancer, in Western and Asian studies, thus, researchers herein compared ddCT vs three-weekly carboplatin and paclitaxel (CT) with respect to progression-free survival (PFS) when administered in first-line treatment of ovarian carcinoma in a single institution in a Western population. Propensity score matching was applied among participants and the final cohort included 69 patients managed with ddCT and 138 CT group. Findings of this retrospective analysis revealed that ddCT resulted in a superior PFS, when compared with CT regimen, as first-line therapy of ovarian carcinoma in a Western population not managed with bevacizumab.